Christopher Raymond
Stock Analyst at Piper Sandler
(3.17)
# 2,257
Out of 4,829 analysts
135
Total ratings
57.89%
Success rate
9.56%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $124.16 | -7.38% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.44 | +1,964.22% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $61.83 | +103.78% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.68 | +138.10% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $3.56 | +124.72% | 7 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $101.16 | +17.64% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $440.95 | +20.88% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $574.70 | +76.27% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $37.12 | +277.16% | 5 | Jan 13, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $43 → $30 | $1.21 | +2,379.34% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $35.83 | +100.97% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $192.05 | +14.55% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.27 | +927.67% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $6.05 | +1,139.67% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $20.60 | +268.93% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.99 | +909.08% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $10.91 | +202.47% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.25 | +211.11% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $6.54 | +542.20% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $5.26 | +318.65% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $2.39 | +67.36% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $5.61 | +345.63% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $275.43 | +4.56% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $29.33 | +39.79% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $51.13 | -45.24% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $74.40 | -46.24% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $2.90 | +3,008.81% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.94 | +4,848.45% | 2 | Mar 13, 2020 |
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $124.16
Upside: -7.38%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.44
Upside: +1,964.22%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $61.83
Upside: +103.78%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.68
Upside: +138.10%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $3.56
Upside: +124.72%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $101.16
Upside: +17.64%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $440.95
Upside: +20.88%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $574.70
Upside: +76.27%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $37.12
Upside: +277.16%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $43 → $30
Current: $1.21
Upside: +2,379.34%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $35.83
Upside: +100.97%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $192.05
Upside: +14.55%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.27
Upside: +927.67%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $6.05
Upside: +1,139.67%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $20.60
Upside: +268.93%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.99
Upside: +909.08%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $10.91
Upside: +202.47%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.25
Upside: +211.11%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $6.54
Upside: +542.20%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $5.26
Upside: +318.65%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $2.39
Upside: +67.36%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $5.61
Upside: +345.63%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $275.43
Upside: +4.56%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $29.33
Upside: +39.79%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $51.13
Upside: -45.24%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $74.40
Upside: -46.24%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $2.90
Upside: +3,008.81%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.94
Upside: +4,848.45%